Opendata, web and dolomites

Olfactomics Surgery SIGNED

BRINGING SURGERY TO THE 21ST CENTURY: REAL-TIME TISSUE ANALYSIS DURING CANCER SURGERY. Improving Patient Safety, Quality and Cost-Effectiveness

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Olfactomics Surgery project word cloud

Explore the words cloud of the Olfactomics Surgery project. It provides you a very rough idea of what is the project "Olfactomics Surgery" about.

2027    preoperative    healthcare    life    intestinal    women    removal    compromising    breast    easily    commercial    optimal    incomplete    solution    innovative    100m    trl    oy    launched    surgery    clinical    time    2015    200    spinoff    currently    team    benefits    removed    breakthrough    university    medical    60    trend    pathological    direct    data    financials    examination    impacts    performed    excellent    instrumentation    follow    invasive    cancer    commercialize    13    skin    law    quality    specialties    ranges    first    revenue    sparing    850m    global    900m    rate    consists    impaired    tissue    300    patient    reoperation    surgical    market    analyze    prostate    specialists    founded    effectiveness    applicable    additional    sensor    olfactomics    company    sold    software    surgeon    reachable    noninvasive    society    tumor    workflow    smoke    international    operation    industry    savings    2019    surgeries    health    connections    saved    hospital    finnish    care    imaging    workplaces    000m    device    minimally    operated    postoperative   

Project "Olfactomics Surgery" data sheet

The following table provides information about the project.

Coordinator
OLFACTOMICS OY 

Organization address
address: AAKKULANKATU 4 C 9
city: TAMPERE
postcode: 33700
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 2˙649˙375 €
 EC max contribution 1˙854˙562 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OLFACTOMICS OY FI (TAMPERE) coordinator 1˙854˙562.00

Map

 Project objective

Currently, cancer tumor removal operation is based on preoperative imaging and postoperative pathological examination. There is a strong global trend towards more tissue-sparing and minimally invasive surgery. If all cancer is not removed in the operation, a reoperation is needed, leading to additional costs, impaired cost-effectiveness and impaired quality of life of the patient. The rate of incomplete removal of a tumor ranges from 10-60%. The breakthrough innovative Olfactomics device allows the surgeon to analyze the operated tissue in real-time during cancer surgery leading to optimal tissue removal without compromising the workflow of the operation and facilitating the use of existing instrumentation. The solution is based on noninvasive, real-time analysis of surgical smoke. The reduced reoperation rate results in significant benefits for the patient, surgeon, hospital and society. The market potential is high. Easily reachable market for the breast cancer surgery is 850M€ and market for other applicable specialties (such as prostate cancer, skin cancer, and intestinal surgery) is over 2,000M€. Olfactomics Oy is a Finnish university-based spinoff company founded in 2015 to commercialize the results of over 10 years of clinical and technical research. The team consists of 13 specialists in surgery, medical technology, software, data analysis, financials and law. The team has excellent connections in the international healthcare industry and sensor technology industry. The technology is currently at TRL 7. The first commercial product for research use will be launched in 2019. This project will focus on scale-up to Olfactomics medical device on breast cancer surgery. The impacts by 2027 include: 3,000 Olfactomics devices sold; 300,000 Olfactomics breast cancer surgeries performed, 70,000 women saved from reoperation, 900M€ costs savings in health care, 100M€ revenue and 200 direct workplaces generated. Scale-up to several surgical areas will follow.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OLFACTOMICS SURGERY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OLFACTOMICS SURGERY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More